Navigating the Increasing Complexity of Drug Biomarker Co-Development

Because of their obvious efficiencies and superior efficacy, the biopharmaceutical industry will continue to focus on targeted medicines in cancer and other therapeutic areas.  Learn about five steps that will help companies better manage the complexity and risk of working in this space.

Previous Article
Early Phase Clinical Unit Tour - Los Angeles
Early Phase Clinical Unit Tour - Los Angeles

Next Article
Early Phase Clinical Unit Tour - Baltimore
Early Phase Clinical Unit Tour - Baltimore

Take a tour